- Home
- OCG vs EDIT Comparison
OCG vs EDIT Comparison
Compare OCG & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCG | EDIT |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 213.8M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | OCG | EDIT |
|---|---|---|
| Price | $0.02 | $2.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 92.1M | 1.8M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $316,807.00 | ★ $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.02 | $0.91 |
| 52 Week High | $19.29 | $4.54 |
Technical Indicators
Market Signals| Indicator | OCG | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 43.16 |
| Support Level | $0.07 | $1.95 |
| Resistance Level | $0.16 | $2.61 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 2.48 | 35.52 |
Price Performance
Historical ComparisonAbout OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.